



AM-101457-1

PTO/SB/08A (07-05)

Approved for use through 07/30/2006.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/574,210
				Filing Date	March 31, 2006
				First Named Inventor	Venkata Ramana Rao <i>et al.</i>
				Art Unit	1615
Examiner Name					
Sheet	2	of	4	Attorney Docket Number	AM-101457-1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	EE	US-6,346,269	2-12-2002	Hsiao et al.	
	FF	US-6,391,342	5-21-2002	Henriksen et al.	
	GG	US-6,479,075	11-12-2002	Odidi et al.	
	HH	US-6,605,303	08-12-2003	Karehill et al.	
	II	US-6,780,436	8-24-2004	Lopez-Cabrera	
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>2</sup> - Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	JJ	WO 01/28559 A1	<del>04-26-2004</del> 4/26/2004	Eisai Co., LTD	English language abstract provided	
	KK	WO 2004/004682 A2	01-15-2004	Laboratorios S.A.L.V.A.T., S.A.		
	LL	WO 2004/004718 A1	01-15-2004	Abbott Laboratories		
	MM	WO 2004/035052 A1	04-29-2004	Takeda Chemical Industries, LTD	English language abstract provided	
	NN	WO 2004/066982 A1	08-12-2004	Ranbaxy Laboratories Limited		
	OO	WO 2004/080439 A1	09-23-2004	Takeda Chemical Industries, LTD	English language abstract provided	

Examiner Signature	/Bethany Barham/	Date Considered	07/29/2009
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BB/

WO 99/27917	Jun., 1999	WO
WO 00/09092	Feb., 2000	WO
WO 2004/004682	Jan., 2004	WO
WO 2004/004718	Jan., 2004	WO
<b>WO 01/28559</b>	Apr., 2004	WO
WO 2004/035052	Apr., 2004	WO
WO 2004/066982	Aug., 2004	WO
WO 2004/080439	Sep., 2004	WO
WO 2004/089333	Oct., 2004	WO
WO 2004/098573	Nov., 2004	WO
WO 2004/098577	Nov., 2004	WO
WO 2004/098594	Nov., 2004	WO
WO 2005/004921	Jan., 2005	WO
WO 2005/001637	Feb., 2005	WO
WO 2005/107721	Nov., 2005	WO

### Other References

Protonix.RTM. drug label revision date Mar. 27, 2001 (also included a text version). cited by examiner .

Chun et al. "Lansoprazole: An Alternative Method of Administration of a Capsule Dosage Formulation" Clinical Therapeutics, vol. 17, No. 3, (1995) p. 441-447. cited by examiner .

Wyeth-Ayerst, Product Information (revised Jul. 10, 2003), Protonix Physician's Desk Reference, 2003, pp. 3461-3464. cited by other .

M. Summers and M. Aulton, Chapter 25 Granulation in Pharmaceutics: Science of Dosage Form Design by Aulton, Michael E., Second ed. (Churchill Livingstone) p. 364, 365, 374. cited by other .

I.C. Rodriguez, Sistemas de liberacion Bioadhesivos (Bioadhesive Release Systems, Bioadhesive delivery systems), Ars Pharmaceutica, 41(1):115-128, 2000. cited by other .

Protonix.RTM. Revised Dec. 2007, Product Literature, "For Delayed-Release Oral Suspension", pp. 1-20. cited by other .

Chun et al, Lansoprazole: An Alternative Method of Administration of a Capsule Dosage Formulation, Clinical Therapeutics, vol. 17, No. 3, pp. 441-447, (May 1995). cited by other .

Protonix, Pantoprazole Sodium, Product Literature, Revised Apr. 2008. cited by other.

*Primary Examiner:* Woodward; M P

*Assistant Examiner:* Barham; Bethany

*Attorney, Agent or Firm:* Carango, Esq.; Paul Howson & Howson LLP

---

### Parent Case Text

---

### CROSS-REFERENCE TO RELATED APPLICATION

This is a continuation of U.S. patent application Ser. No. 10/955,567, filed Sep. 30, 2004, which claims the benefit under 35 USC 119(e) of prior U.S. Provisional Patent Application No. 60/507,810, filed Oct.